SMMT
Summit Therapeutics Inc.
Summit Therapeutics Inc. insider trading
Summit Therapeutics Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Miami, FL. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent SMMT insider transactions
3 insiders traded SMMT on the open market between Jun 04, 2026 and Jun 12, 2026 — 6 purchases worth $103.6M.
- Bought
- $103.6M
- Sold
- —
- Net
- +$103.6M
- Insiders
- 3
Zanganeh Mahkam
Co-Chief Executive Officer · Director
+$50M
Jun 12, 2026
3,810,000 sh · $13.12
Duggan Robert W
Co-Chief Executive Officer · Director
+$50M
Jun 12, 2026
3,810,000 sh · $13.12
Duggan Robert W
Co-Chief Executive Officer · Director
+$1.5M
Jun 04, 2026
100,000 sh · $14.60
Zanganeh Mahkam
Co-Chief Executive Officer · Director
+$1.5M
Jun 04, 2026
100,000 sh · $14.60
Soni Manmeet Singh
COO and CFO · Director
+$361.5K
Jun 04, 2026
25,000 sh · $14.46
Soni Manmeet Singh
COO and CFO · Director
+$360.8K
Jun 04, 2026
25,000 sh · $14.43
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Zanganeh MahkamCo-Chief Executive Officer · Director | 3,810,000 | $13.12 | +$50M |
| Jun 12, 2026 | Duggan Robert WCo-Chief Executive Officer · Director | 3,810,000 | $13.12 | +$50M |
| Jun 04, 2026 | Duggan Robert WCo-Chief Executive Officer · Director | 100,000 | $14.60 | +$1.5M |
| Jun 04, 2026 | Zanganeh MahkamCo-Chief Executive Officer · Director | 100,000 | $14.60 | +$1.5M |
| Jun 04, 2026 | Soni Manmeet SinghCOO and CFO · Director | 25,000 | $14.46 | +$361.5K |
| Jun 04, 2026 | Soni Manmeet SinghCOO and CFO · Director | 25,000 | $14.43 | +$360.8K |
SEC Form 4 data, Q3 2024 to Q2 2026
SMMT insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 4 insiders traded SMMT on the open market: 11 purchases worth $124.6M and 0 sales. In the last four quarters alone: 11 purchases ($124.6M) and 0 sales, by 4 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | +$102.2M5 buys | — | |
| Q1 2026 | — | — | |
| Q4 2025 | +$10.5M2 buys | — | |
| Q3 2025 | +$12M4 buys | — | |
| Q2 2025 | — | — | |
| Q1 2025 | — | — | |
| Q4 2024 | — | — | |
| Q3 2024 | — | — |
- Largest purchase
- +$50M of SMMT by Zanganeh Mahkam (Co-Chief Executive Officer · Director) on Jun 12, 2026.
Open-market transactions through Jun 30, 2026most recent first
Xia Yu
Director
+$10M
Oct 21, 2025
533,617 sh · $18.74
Duggan Robert W
Co-Chief Executive Officer · Director
+$500K
Oct 21, 2025
26,680 sh · $18.74
Zanganeh Mahkam
Co-Chief Executive Officer · Director
+$90.4K
Sep 11, 2025
5,000 sh · $18.07
Duggan Robert W
Co-Chief Executive Officer · Director
+$90.4K
Sep 11, 2025
5,000 sh · $18.07
Zanganeh Mahkam
Co-Chief Executive Officer · Director
+$5.9M
Sep 10, 2025
333,394 sh · $17.68
Duggan Robert W
Co-Chief Executive Officer · Director
+$5.9M
Sep 10, 2025
333,394 sh · $17.68
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Oct 21, 2025 | Xia YuDirector | 533,617 | $18.74 | +$10M |
| Oct 21, 2025 | Duggan Robert WCo-Chief Executive Officer · Director | 26,680 | $18.74 | +$500K |
| Sep 11, 2025 | Zanganeh MahkamCo-Chief Executive Officer · Director | 5,000 | $18.07 | +$90.4K |
| Sep 11, 2025 | Duggan Robert WCo-Chief Executive Officer · Director | 5,000 | $18.07 | +$90.4K |
| Sep 10, 2025 | Zanganeh MahkamCo-Chief Executive Officer · Director | 333,394 | $17.68 | +$5.9M |
| Sep 10, 2025 | Duggan Robert WCo-Chief Executive Officer · Director | 333,394 | $17.68 | +$5.9M |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Summit Therapeutics Inc. company record
- SEC industry classification
- Pharmaceutical Preparations
- Headquarters
- Miami, FL
- Listed on
- Nasdaq
- SEC Central Index Key
- 0001599298
- Previously filed as
- Summit Therapeutics plc
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought SMMT
What the stock actually did in the 90 days following each open-market purchase
Don't check SMMT — let it ping you
Get told the moment an insider moves on SMMT
Pro watches Summit Therapeutics Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add SMMT to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read SMMT insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Are SMMT insiders buying or selling?
- Between Jun 04, 2026 and Jun 12, 2026, 3 Summit Therapeutics Inc. insiders made 6 open-market purchases worth $103.6M and no sales, a net purchase of $103.6M.
- How much SMMT stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 4 Summit Therapeutics Inc. insiders made 11 open-market purchases worth $124.6M and no sales. In the four quarters to Jun 30, 2026: 11 purchases ($124.6M) and no sales. The largest purchase was Zanganeh Mahkam buying $50M on Jun 12, 2026.
- What was the largest recent SMMT insider trade?
- Zanganeh Mahkam (Co-Chief Executive Officer · Director) bought $50M of SMMT stock on Jun 12, 2026 at about $13.12 a share.
- When did an insider last buy SMMT shares?
- The most recent open-market purchase on file is Zanganeh Mahkam (Co-Chief Executive Officer · Director) buying $50M on Jun 12, 2026.
- Where does SMMT insider trading data come from?
- From the Form 4 filings Summit Therapeutics Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.